The prognostic value of skeletal muscle index on clinical and survival outcomes after cytoreduction and HIPEC for peritoneal metastases from colorectal cancer: A systematic review and meta-analysis

Giorgio, Andrea Di; Rotolo, Stefano; Cintoni, Marco; Rinninella, Emanuele; Pulcini, Gabriele; Schena, Carlo Alberto; Ferracci, Federica; Grassi, Futura; Raoul, Pauline; Moroni, Rossana; Pacelli, Fabio; Gasbarrini, Antonio; Mele, Maria Cristina

doi:10.1016/j.ejso.2021.10.008

Cited by 12 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary sarcopenia is caused by the coexistence of multiple pathogenic mechanisms involving the increase in apoptotic activity in muscle cells, the production of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, the presence of oxidative stress, and accumulation of oxygen radicals, low energy and protein intake [41]. Even before the tumor diagnosis, it is possible that these mechanisms, especially the neoplastic, inflammatory, microenvironmental (TNF, IL-1, proteolysis-inducing factor), and physical inactivity [42], play a role in the pathogenesis of sarcopenia. In our opinion, such a high rate of sarcopenia at diagnosis in children with soft tissue and bone sarcomas could also be related to the diagnostic delay of these tumors [43].…”

Section: Discussionmentioning

confidence: 99%

“…By comparing the mean value of tPMA at diagnosis and after 12 months, we observed a statistically significant reduction in the tPMA Z-score. This change during treatment may probably be caused by an inadequate intake of energy or proteins (due to anorexia, nausea, vomiting, malabsorption related to the oncologic treatments), already associated with the inflammatory state and hypomobility [42]. A reduced intake of nutrients during cancer treatment can be associated with sarcopenia diagnosis or can worsen its severity if already present before initiating treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed)

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: We evaluated nutritional and sarcopenia status and their clinical impact in pediatric patients affected by bone and soft tissue sarcomas. Methods: Body mass index (BMI), prognostic nutritional index (PNI), and total psoas muscle area (tPMA) at diagnosis and after 12 months were analyzed. tPMA was measured from single cross-sectional computed tomography (CT) images at L4–L5. Age-specific and sex-specific tPMA Z-scores were retrieved from an online calculator. Results: A total of 21 patients were identified between February 2013 and December 2018. Twelve patients (57.1%) experienced sarcopenia at diagnosis, although not statistically associated with overall survival (OS) (p = 0.09). BMI Z-score, PNI, and tPMA Z-score significantly decreased between diagnosis and after 12 months of treatment (p < 0.05). Univariate analysis showed significant associations between poor OS and the presence of metastasis (p = 0.008), the absence of surgery (p = 0.005), PNI decrease (p = 0.027), and the reduction in tPMA > 25% (p = 0.042) over the 12 months. Conclusions: Sarcopenia affects more than half of the patients at diagnosis. Decreased PNI during 12 months of treatment has significant predictive value for OS. The role of tPMA derived from CT scan among pediatric patients with sarcoma should be investigated in further prospective and larger studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed)

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Different papers suggest an association between body composition and treatment related toxicity. In particular, sarcopenia is related with an increased incidence of severe adverse reactions and treatment interruption [ 40 , 41 , 42 , 43 ]. In patients with pancreatic neoplasm, results are still not conclusive [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: Pancreatic cancer incidence is growing, but the prognosis for survival is still poor. Patients with pancreatic cancer often suffer from malnutrition and sarcopenia, two clinical conditions that negatively impact oncological clinical outcomes. The aim of this systematic review was to analyze the impact of different nutritional interventions on clinical outcomes in patients with pancreatic cancer during chemotherapy. Methods: A systematic review of MedLine, EMBASE, and Web of Science was carried out in December 2022, identifying 5704 articles. Titles and abstracts of all records were screened for eligibility based on inclusion criteria, and nine articles were included. Results: All nine articles included were prospective studies, but a meta-analysis could not be performed due to heterogenicity in nutritional intervention. This Systematic Review shows an improvement in Quality of Life, nutritional status, body composition, oral intake, and Karnofsky Performance Status, following nutritional interventions. Conclusions: This Systematic Review in pancreatic cancer patients during chemotherapies does not allow one to draw firm conclusions. However, nutritional support in pancreatic cancer patients is advisable to ameliorate oncological care. Further well-designed prospective studies are needed to identify nutritional support’s real impact and to establish a reliable way to improve nutritional status of pancreatic cancer patients during chemotherapy.

show abstract

“…Several studies are currently investigating the factors affecting the posttreatment complications of CRS + HIPEC, aiming to reduce these as far as possible. Rotolo et al [ 44 ] observed that the presence of low skeletal muscle mass at diagnosis influences the development of postoperative complications after CRS in patients with colorectal cancer and PM. Morgan et al [ 45 ] reported that mutation of the RAS gene independently predicted early tumor recurrence after CRS + HIPEC, suggesting that this could be used for the identification of patients who may not benefit from the procedure.…”

Section: Discussionmentioning

confidence: 99%

Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis

Wang

Chen

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Peritoneal metastasis often occurs in patients with colorectal cancer peritoneal metastasis, and the prognosis is poor. A large body of evidence highlights the beneficial effects of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, but to date, there is little consensus on the optimal treatment strategy for patients with colorectal cancer peritoneal metastasis. The purpose of this study is to evaluate the impact of CRS + HIPEC on survival and provide reference for the treatment of patients with colorectal cancer peritoneal metastasis. Methods This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PubMed, Embase, Cochrane, Web of Knowledge, and ClinicalTrials.gov databases were screened from inception of the review to March 11, 2022. Ten studies were included in qualitative and quantitative analysis. Results A total of 3200 patients were enrolled in the study, including 788 patients in the CRS and HIPEC groups and 2412 patients in the control group, of which 3 were randomized controlled trials and 7 were cohort studies. The 3 randomized controlled studies were of high quality, and the quality scores of the 7 cohort studies were all 7 or above, indicating high quality. The results showed that the OS of CRS + HIPEC group was higher than that of control group (HR: 0.53, 95% CI: 0.38–0.73; P < 0.00001, I2 = 82.9%); the heterogeneity of the studies was large. The subgroup analysis showed that the OS of CRS and HIPEC group was higher than that of PC group (HR: 0.37, 95% CI: 0.30–0.47; P = 0.215, I2 = 31%) and higher than that in CRS group (HR: 0.73, 95% CI: 0.49–1.07; P = 0.163, I2 = 44.8%); the heterogeneity of the studies was low. In the OPEN group, the OS of THE CRS and HIPEC groups was higher than that in the control group (HR: 0.51, 95% CI: 0.38–0.70; P = 0.353, I2 = 3.9%); OPEN group showed lower heterogeneity. The OS of 60–100-min group was higher than that in the control group (HR: 0.65, 95% CI: 0.49–0.88; P = 0.172, I2 = 37.4%); the heterogeneity of the studies was low. Sensitivity analysis showed that there was no significant difference in the results of the combined analysis after each study was deleted. The results of publication bias showed that the P-value of Egger and Begg tests was 0.078 > 0.05, indicating that there is no publication bias. Conclusions CRS + HIPEC can improve the survival rate of patients with colorectal cancer peritoneal metastasis

show abstract

The prognostic value of skeletal muscle index on clinical and survival outcomes after cytoreduction and HIPEC for peritoneal metastases from colorectal cancer: A systematic review and meta-analysis

Cited by 12 publications

References 49 publications

Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed)

Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed)

Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies

Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis

Contact Info

Product

Resources

About